A new CAR-T drug on the market
Gilead has scored a new CAR-T approval: Tecartus, the cell therapy made by Kite Pharma, has won FDA approval to treat mantle cell lymphoma. The drug is actually quite similar to its predecessor, Yescarta. Both CAR-T drugs are anti-CD19 therapies, and both launched with a price tag of $373,000. The biggest difference seems to be its manufacturing process, FiercePharma points out. There's one other CAR-T product on the market: Kymriah, made by Novartis.
No hay comentarios:
Publicar un comentario